DVA Stock Analysis — DaVita Inc.
Sector: Healthcare
AI Verdict
DaVita trades at a bargain multiple for its expected growth, but the current price bakes in a lot of optimism and is vulnerable to a sharp technical correction.
Competitive Moat
DaVita operates dialysis clinics across the U.S., benefiting from high regulatory barriers and long-term patient relationships that make switching providers costly and disruptive. Its scale allows for efficient operations and negotiating power with payers, creating a durable competitive edge in a heavily regulated market.
Summary
DaVita's 36.5% expected EPS growth and 13.6x forward P/E stand out as the market prices in a sharp earnings rebound.
Where It Stands
Shares are up 37.36% over the past year with an RSI of 84.2 (deeply overbought) and trade at 13.6x next year's earnings, a discount to the healthcare sector median of 22x.
Key Metrics
- RSI: 84.2 — Overbought
- Trailing P/E: 18.5x
- Forward P/E: 13.6x
- PEG Ratio: 0.49
- Earnings Growth: +0.4%
- Revenue Growth: +0.1%
- Market Cap: $12.8B
- 1-Year Return: 37.36%
- 52-Week High: $202.69
- 52-Week Low: $101.00
Analyst Consensus
6 Buy · 7 Hold · 1 Sell (14 analysts)
Bull Case
You're paying just 13.6x forward earnings for 36.5% EPS growth, which is cheap for the growth on offer if DaVita's regulatory moat holds.
Bear Case
With an RSI of 84.2, the stock is extremely overbought and a pullback to a neutral RSI could mean a 10–20% drop even if fundamentals don't change.
Catalyst to Watch
Watch for regulatory changes or reimbursement updates, as shifts here could directly impact DaVita's earnings power and the defensibility of its moat.